Adeza Biomedical Corp (902482) SEC Filing 10-K Annual report for the fiscal year ending Friday, December 31, 2004

Adeza Biomedical Corp

CIK: 902482

Exhibit 99.1


Mark Fischer-Colbrie
  Jody Cain (
Chief Financial Officer
  Bruce Voss (
Adeza Biomedical Corporation
  Lippert/Heilshorn & Associates, Inc.
(408) 745-0975
  (310) 691-7100


Reports 10th Consecutive Quarter of Profitability on Record Product Sales

SUNNYVALE, Calif. (March 9, 2005)

– Adeza (NASDAQ: ADZA) today announced financial results for the three months and year ended December 31, 2004.

For the three months ended December 31, 2004, Adeza posted its 10th consecutive profitable quarter. The company reported that net income for the fourth quarter of 2004 was $1.6 million, an increase of $436,000 or 38% from net income of $1.2 million for the fourth quarter of 2003. Diluted net income per share for the fourth quarter of 2004 was $0.11 based on 14.5 million shares outstanding, compared with diluted net income per share of $0.09 based on 12.8 million shares outstanding for the fourth quarter of 2003. The change in share count is primarily attributed to the completion in December 2004 of the company’s initial public offering of 4.3 million common shares.

Adeza reported record quarterly product sales for the fourth quarter of 2004 of $9.2 million, an increase of $1.9 million or 26%, compared with product sales of $7.3 million for the fourth quarter of 2003. The increase in the 2004 fourth quarter is primarily attributed to higher unit sales of the Fetal Fibronectin Test.

For the three months ended December 31, 2004, selling and marketing expenses were $4.3 million, compared with $3.2 million for the comparable period in 2003, due mainly to additional field sales representatives, costs associated with increased headcount and expansion of marketing programs. General and administrative expenses for the fourth quarter of 2004 were $1.4 million, compared with $940,000 in the prior-year fourth quarter, due primarily to headcount related costs. Research and development expenses increased to $697,000 for the fourth quarter of 2004, compared with $481,000 for the fourth quarter of 2003, due mainly to costs related to clinical studies.

For the year ended December 31, 2004, Adeza reported net income of $8.9 million, or $0.65 per diluted share based on 13.6 million shares outstanding, compared with net income of $3.2 million, or $0.26 per diluted share based on 12.5 million shares outstanding, for the year ended December 31, 2003. Cost of product sales for 2004 included a one-time benefit of $2.7 million.

For the year ended December 31, 2004, the company reported product sales of $33.6 million, an increase of $7.1 million from $26.5 million for the year ended December 31, 2003.

As of December 31, 2004, Adeza had cash and cash equivalents of $80.1 million, stockholders’ equity of $81.7 million and working capital of $81.3 million. The company’s cash position as of December 31, 2004 reflects net proceeds of $61.9 million from the company’s initial public offering.


The following information was filed by Adeza Biomedical Corp on Wednesday, March 9, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adeza Biomedical Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adeza Biomedical Corp.


Assess how Adeza Biomedical Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adeza Biomedical Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 902482
Form Type: 10-K Annual Report
Accession Number: 0000950134-05-006256
Submitted to the SEC: Tue Mar 29 2005 5:23:10 PM EST
Accepted by the SEC: Tue Mar 29 2005
Period: Friday, December 31, 2004
Industry: Instruments For Meas And Testing Of Electricity And Elec Signals

External Resources:

Bookmark the Permalink: